Загрузка...
Recent advances on blinatumomab for acute lymphoblastic leukemia
Although complete remission rate of B cell acute lymphoblastic leukemia (B-ALL) has improved significantly over the past few decades, patients with relapsed/refractory ALL still have dismal outcome. Tyrosine kinase inhibitors, antibody–drug conjugates and chimeric antigen receptor T cell therapy are...
Сохранить в:
| Опубликовано в: : | Exp Hematol Oncol |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6833142/ https://ncbi.nlm.nih.gov/pubmed/31709129 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-019-0152-y |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|